TY - JOUR
T1 - Specialized pro-resolving lipid mediators
T2 - The future of chronic pain therapy?
AU - Chávez-Castillo, Mervin
AU - Ortega, Ángel
AU - Cudris-Torres, Lorena
AU - Duran, Pablo
AU - Rojas, Milagros
AU - Manzano, Alexander
AU - Garrido, Bermary
AU - Salazar, Juan
AU - Silva, Aljadis
AU - Rojas-Gomez, Diana Marcela
AU - De Sanctis, Juan B.
AU - Bermúdez, Valmore
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - Chronic pain (CP) is a severe clinical entity with devastating physical and emotional con-sequences for patients, which can occur in a myriad of diseases. Often, conventional treatment ap-proaches appear to be insufficient for its management. Moreover, considering the adverse effects of traditional analgesic treatments, specialized pro-resolving lipid mediators (SPMs) have emerged as a promising alternative for CP. These include various bioactive molecules such as resolvins, maresins, and protectins, derived from ω-3 polyunsaturated fatty acids (PUFAs); and lipoxins, pro-duced from ω-6 PUFAs. Indeed, SPMs have been demonstrated to play a central role in the regulation and resolution of the inflammation associated with CP. Furthermore, these molecules can mod-ulate neuroinflammation and thus inhibit central and peripheral sensitizations, as well as long-term potentiation, via immunomodulation and regulation of nociceptor activity and neuronal pathways. In this context, preclinical and clinical studies have evidenced that the use of SPMs is beneficial in CP-related disorders, including rheumatic diseases, migraine, neuropathies, and others. This review integrates current preclinical and clinical knowledge on the role of SPMs as a potential therapeutic tool for the management of patients with CP.
AB - Chronic pain (CP) is a severe clinical entity with devastating physical and emotional con-sequences for patients, which can occur in a myriad of diseases. Often, conventional treatment ap-proaches appear to be insufficient for its management. Moreover, considering the adverse effects of traditional analgesic treatments, specialized pro-resolving lipid mediators (SPMs) have emerged as a promising alternative for CP. These include various bioactive molecules such as resolvins, maresins, and protectins, derived from ω-3 polyunsaturated fatty acids (PUFAs); and lipoxins, pro-duced from ω-6 PUFAs. Indeed, SPMs have been demonstrated to play a central role in the regulation and resolution of the inflammation associated with CP. Furthermore, these molecules can mod-ulate neuroinflammation and thus inhibit central and peripheral sensitizations, as well as long-term potentiation, via immunomodulation and regulation of nociceptor activity and neuronal pathways. In this context, preclinical and clinical studies have evidenced that the use of SPMs is beneficial in CP-related disorders, including rheumatic diseases, migraine, neuropathies, and others. This review integrates current preclinical and clinical knowledge on the role of SPMs as a potential therapeutic tool for the management of patients with CP.
KW - Central nervous system sensitization
KW - Chronic pain
KW - Eicosanoids
KW - Inflammation
KW - Long-term poten-tiation
KW - Nociception
KW - Omega 3 fatty acids
KW - Pain management
KW - Polyunsaturated fatty acids
KW - Specialized pro-resolving lipid mediators
UR - http://www.scopus.com/inward/record.url?scp=85115787392&partnerID=8YFLogxK
U2 - 10.3390/ijms221910370
DO - 10.3390/ijms221910370
M3 - Review article
AN - SCOPUS:85115787392
SN - 1661-6596
VL - 22
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 19
M1 - 370
ER -